Literature DB >> 8424026

Serum bactericidal test as a prognostic indicator in acute pulmonary exacerbations of cystic fibrosis.

P Cahen1, M Le Bourgeois, C Delacourt, C Coustère, P Nicaise, J de Blic, M Véron, P Scheinmann, J L Gaillard.   

Abstract

The serum bactericidal test has been used for many years for optimal assessment of the efficacy of antibiotic therapy in patients with infective endocarditis and other bacterial infections. Its capacity to predict the bacteriological outcome of acute pulmonary exacerbations in patients with cystic fibrosis was evaluated. A total of 54 courses of intravenous antibiotic therapy were analyzed in 22 patients, whose ages ranged from 4 months to 24 years (mean age: 10 years). The serum bactericidal activity of blood samples, taken at expected peak and trough antibiotic levels on day 4 of therapy, were determined against the potentially pathogenic strains isolated in sputum at the time of admission. For 104 isolates (64 Pseudomonas aeruginosa, 28 Staphylococcus aureus, and 12 Haemophilus influenzae strains), the peak and trough bactericidal titers were compared to bacteriological outcome. Bacteriological success was defined as a decrease of 2 log10 units or more in the bacterial density in sputum between days 0 and 7 of therapy. At peak antibiotic levels, serum bactericidal titers of 1:128 or more were 96% (all isolates) and 89% (P aeruginosa isolates), predictive of cure, whereas serum bactericidal titers of less than 1:16 were 100% predictive of failure for all infecting bacteria. In patients aged less than 18 years, the best peak titer for predicting success was 1:64, with a predictive value of 96% for titers of 1:64 or greater. The peak titer that best predicted success in patients aged 18 years or more was 1:128, with a predictive value of only 83% for titers of 1:128 or greater.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8424026

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  5 in total

Review 1.  Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis.

Authors:  N Høiby
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

2.  Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis.

Authors:  J L Gaillard; P Cahen; C Delacourt; C Silly; M Le Bourgeois; C Coustère; J de Blic; G Lenoir; P Scheinmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

3.  Peritoneal fluid titer test for peritoneal dialysis-related peritonitis.

Authors:  Christine Strijack; Godfrey K M Harding; Robert E Ariano; Sheryl A Zelenitsky
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

4.  Polymyxin Combination Therapy and the Use of Serum Bactericidal Titers in the Management of KPC-Producing Klebsiella pneumoniae Infections: A Report of 3 Cases.

Authors:  Eric Gomez; Martha Sanchez; Zonaira Gul; Carl Urban; Noriel Mariano; Robert H K Eng; David B Huang; Tom Chiang
Journal:  Case Rep Med       Date:  2011-11-28

Review 5.  Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.

Authors:  Charles W Stratton
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.